See today's BioWorld Asia
To read the full story, subscribe or sign in.

Alphamab and JMT-Bio ink $439M antibody-drug conjugate China deal

Oct. 1, 2024
By Tamra Sami
Jiangsu Alphamab Biopharmaceuticals Co. Ltd. is out-licensing its anti-HER2 bispecific antibody-drug conjugate, JSKN-003, to JMT-Bio Technology Co. for China rights in a deal worth up to ¥3.08 billion (US$439 million) plus sales royalties.
BioWorld Asia Deals and M&A Cancer Antibody-drug conjugate Asia-Pacific China